International Congress Organising Committee competing interests

None to declare

None to declare

• President, Society for the Study of Addiction
• Trustee, Student Minds
• Consultant Psychiatrist, Central North West London NHS Foundation Trust

None to declare

None to declare

I have received honorarium/speaker or advisory fees from the following: Teva, Bristol Myers Squibb, Boehringer Ingelheim, Recordati, Lundbeck, Otsuka, Janssen, CNX Therapeutics, Sunovion, ROVI Biotech, Karuna therapeutics, Novartis. Part of SF research was funded by an unrestricted educational grant from Sunovion Pharmaceuticals

I have received research support from Compass Pathways and Orchard OCD as well as NIHR, UKRI, Horizon Europe, British Council.. I have received support for attending meetings and/or travel from International Society for Behavioural Addiction, World Federation of Societies of Biological Psychiatry, International College of Neuropsychopharmacology, Albatros International College of Addictology, International Forum of Mood and Anxiety Disorders, British Association for Psychopharmacology

None to declare

None to declare

None to declare

RCPsych related RS is the chair of the faculty of psychiatry of intellectual disability. He is the Associate Dean for Academic Training. He is ex-chair of the RCPsych South-west division. Non-RCPsych related RS developed the non-commercial and free to use SUDEP and Seizure Safety Checklist (https://sudep.org/about-research/sudep-and-seizure-safety-checklist/) and the EpSMon app (https://sudep.org/about-research/epsmon-app/) to reduce the risk of SUDEP and enhance seizure safety. RS is the chief Investigator of the NIHR adopted national Ep-ID register. The Register is supported and monitored by the National Institute of Health Research UK. The funding for each molecule examined by the Register is via an Investigator Initiated Support grant from each of the molecule’s parent company. The funding is to RS’s NHS institution and goes towards the salary of the research coordinator and the institution’s project oversight costs. The contributing companies till date include Eisai, UCB, Bial, Jazz pharma (previously GW pharma) and Angelini. In addition to the above RS has received institutional research, travel support and/or honorarium for talks and expert advisory boards from LivaNova, UCB, Eisai, Neuraxpharm, Veriton Pharma, Bial, Angelini, UnEEG and Jazz/GW pharma. He holds competitive grants from various national grant bodies including Innovate, Economic and Social Research Council (ESRC), Engineering and Physical Sciences Research Council (ESPRC), National Institute of Health Research (NIHR), NHS Small Business Research Initiative (SBRI) and other funding bodies including various charities.

None to declare

Employed by Imperial and King's College London; Honorary Consultant UK NHS, Editor of Journal of Psychopharmacology and Deputy Editor, BJPsych Open, Paid lectures and advisory boards for the following companies with drugs used in affective and related disorders: Flow Neuroscience, Novartis, Roche, Janssen, Takeda, Noema pharma, Compass, Astrazenaca, Boehringer Ingelheim, Eli Lilly, LivaNova, Lundbeck, Sunovion, Servier, Allegan, Bionomics, Sumitomo Dainippon Pharma, Sage, Neurocentrx, Otsuka Principal Investigator in the Restore-Life VNS registry study funded by LivaNova. Principal Investigator on ESKETINTRD3004: “An Open-label, Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression.” Principal Investigator on “The Effects of Psilocybin on Cognitive Function in Healthy Participants” Principal Investigator on “The Safety and Efficacy of Psilocybin in Participants with Treatment-Resistant Depression (P-TRD)” Principal Investigator on ‘’A Double-Blind, Randomized, Parallel-Group Study with Quetiapine Extended Release as Comparator to Evaluate the Efficacy and Safety of Seltorexant 20 mg as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Disorder with Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy.’’ (Janssen) Principal Investigator on ‘’ An Open-label, Long-term, Safety and Efficacy Study of Aticaprant as Adjunctive Therapy in Adult and Elderly Participants with Major Depressive Disorder (MDD).’’ (Janssen) Principal Investigator on ‘’A Randomized, Double-blind, Multicentre, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy.’’ Principal Investigator on ‘’ A Study of Disease Characteristics and Real-life Standard of Care Effectiveness in Patients with Major Depressive Disorder (MDD) With Anhedonia and Inadequate Response to Current Antidepressant Therapy Including an SSRI or SNR.’’ (Janssen) UK Chief Investigator for Compass; COMP006 & COMP007 studies UK Chief Investigator for Novartis MDD study MIJ821A12201 Grant funding (past and present): NIMH (USA); CIHR (Canada); NARSAD (USA); Stanley Medical Research Institute (USA); MRC (UK); Wellcome Trust (UK); Royal College of Physicians (Edin); BMA (UK); UBC-VGH Foundation (Canada); WEDC (Canada); CCS Depression Research Fund (Canada); MSFHR (Canada); NIHR (UK). Janssen (UK) EU Horizon 2020 No shareholdings in pharmaceutical companies